SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

Trial Profile

SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2018

At a glance

  • Drugs Landipirdine (Primary)
  • Indications Parkinson's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SYNAPSE
  • Sponsors Biotie Therapies Corp.
  • Most Recent Events

    • 17 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 08 Jan 2018 According to the Acorda Therapeutics media release, company continues to review the data which will be presented at an upcoming medical meeting.
    • 01 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top